Real-life Study on the Use of Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Relapsed/Refractory Multiple Myeloma

Studio Real-life Sull'Utilizzo Del Trapianto Allogenico di Cellule Staminali Ematopoietiche in Pazienti Affetti da Mieloma Multiplo Recidivato Refrattario

A multicenter, non-interventional, observational, retrospective and prospective pharmacological study aimed at evaluating the use of allogeneic hematopoietic stem cell transplantation in patients with relapsed/refractory multiple myeloma.

Inclusion Criteria:

• patients diagnosed with relapsed/refractory multiple myeloma according to IMWG criteria who have undergone allogeneic hematopoietic stem cell transplantation;
• Age ≥ 18 years;
• Signature of the informed consent form (where possible).

Exclusion Criteria:

• Patients diagnosed with primary AL amyloidosis, monoclonal gammopathy of undetermined significance (MGUS), indolent multiple myeloma, or primary plasma cell leukemia;
• Patients who have not undergone allogeneic hematopoietic stem cell transplantation;
• Age < 18 years.